Mandeep R. Mehra (born December 1967 in Delhi) is The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine and a professor of medicine at Harvard Medical School. He is the medical director of the Brigham Heart and Vascular Center in Boston, Massachusetts, and specializes in advanced heart failure, mechanical circulatory support and cardiac transplantation.
Narrowing of the coronary arteries, or cardiac allograft vasculopathy (CAV), after a heart transplant has been noted as a significant problem in terms of long-term survival. The terminology used in past research has varied, causing difficulties in interpreting which treatments benefit. In 2010, Mehra led the first international consensus document from the ISHLT working group on the classification of CAV, standardising the nomenclature used and therefore defining the best way to identify CAV.[3] His paper on allograft vasculopathy was accepted for presentation at the ISHLT in Venice.[1]
On May 1, 2020, Mehra was the lead author of a small group who published results of an analysis[5] of data from 169 hospitals collected via a database funded by Surgisphere to assess the risk of in-hospital death among patients with cardiovascular disease infected with SARS-CoV2 in the New England Journal of Medicine. On May 22, 2020, the same group published another analysis[6] of the Surgisphere data in The Lancet describing outcomes in patients treated with hydroxychloroquine with or without a macrolide for patients with COVID-19. The latter paper resulted in the World Health Organization Director-General Tedros Adhanom Ghebreyesus announcing the temporary halt of hydroxychloroquine arm of its Solidarity Trial of therapies for COVID-19.[7] The provenance and validity of the data and database on which both papers rely was questioned,[8] and an expression of concern was published in The Lancet[9] and in the NEJM.[10] Mehra, Ruschitzka, and Patel quickly hired an independent company to conduct an audit of the Surgisphere data.[11] On June 4, Mehra and two of his co-authors retracted The Lancet paper that had raised caution about the safety of hydroxychloroquine, due to inability to gain access to the data in the audit. “We can no longer vouch for the veracity of the primary data sources,” Mehra and his co-authors wrote.[12]
As the NEJM study used data from Surgisphere, the authors also withdrew that study.[13] In the meantime, the same authors pulled a pre-print publication claiming effectiveness of ivermectin, an anthelmintic, in treating coronavirus from the pre-print server, as this paper also relied on the same Surgisphere data source. However, the study had already led to Peru, Bolivia, Paraguay, Colombia and Chile using the drug for COVID-19 treatment.[14][15] Mehra apologised for rushing to publish during the COVID-19 crisis: "I did not do enough to ensure that the data source was appropriate for this use. For that, and for all the disruptions—both directly and indirectly—I am truly sorry."[14] Dr. Richard Horton, editor in chief of The Lancet, called the paper a fabrication and "a monumental fraud". Dr. Eric Rubin, editor in chief of NEJM, said "We shouldn’t have published this".[16]
Mehra was introduced to Surgisphere founder Sapan Desai by colleague Amit Patel. It was later found that Desai and Patel were brothers-in-law, and that Patel's position at the University of Utah was terminated.[17]
Appointments
He became the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine and a professor of medicine at Harvard Medical School and medical director of the Brigham Heart and Vascular Center in Boston, Massachusetts.[18] He specializes in advanced heart failure, mechanical circulatory support and cardiac transplantation.[19]
Mehra served as president of the ISHLT in 2008-2009[20] and became editor-in-chief of the society's journal, the Journal of Heart and Lung Transplantation.[2][21][22]
In 2016, he was appointed president of the Heart Failure Society of America.[2][23]
Selected publications
He has published more than 500 manuscripts, abstracts, and book chapters in areas of immunosuppression, genomic medicine, cardiac transplant rejection, guidelines for listing patients for a heart transplant, and in mechanical circulatory support.[23]
^Servick, Kelly (2 June 2020). "A mysterious company's coronavirus papers in top medical journals may be unraveling". Science. doi:10.1126/science.abd1337. S2CID219924933.
^ abPiller, Charles (4 June 2020). "Two elite medical journals retract coronavirus papers over data integrity questions". Science. doi:10.1126/science.abd1697. S2CID219915006.
